Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

OncoSil secures FDA approval for targeted bile duct cancer device

18 August 2026 · By · Wire by Fusion42

Published

18 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at biotechdispatch.com.au →

◆ Verified

Fusion42 · 18 August 2026 · Fusion42 review

OncoSil Medical received FDA approval under the Humanitarian Device Exemption for its OncoSil device to treat unresectable, non-metastatic distal cholangiocarcinoma, enabling market entry in the US with a limited initial commercial rollout.

This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 17 Aug 2026 and 18 Aug 2026.

◆ ◆ The Wire takeaway

You now have a clear path to launch a high-value treatment for a rare bile duct cancer in the US under FDA’s Humanitarian Device Exemption. Locking in partnerships with top cancer centres and preparing reimbursement claims is your immediate priority.

◆ Coverage

4 sources · first reported 17 Aug 2026 · latest 18 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalmedtechcancer-treatmenthumanitarian-deviceus-market